SVREW vs GKOS vs ATRC vs LFMD vs NVCR

For growth investors, Glaukos Corporation (GKOS) is the stronger pick with 32.

3% revenue growth year-over-year, versus -38. 1% for SaverOne 2014 Ltd (SVREW). Analysts rate Glaukos Corporation (GKOS) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Glaukos Corporation (GKOS) delivered a total return of +74.

7%, compared to -96. 4% for SaverOne 2014 Ltd (SVREW). Over 10 years, the gap is even starker: GKOS returned +454. 5% versus SVREW's -96. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AtriCure, Inc.

(ATRC) is the lower-risk stock at 0. 95β versus LifeMD, Inc. 's 2. 27β — meaning LFMD is approximately 140% more volatile than ATRC relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Glaukos Corporation (GKOS) is pulling ahead at 32.

3% versus -38. 1% for SaverOne 2014 Ltd (SVREW). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -18. 4% for Glaukos Corporation. Over a 3-year CAGR, SVREW leads at 55. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AtriCure, Inc.

(ATRC) is the more profitable company, earning -2. 1% net margin versus -20. 8% for SaverOne 2014 Ltd — meaning it keeps -2. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ATRC leads at -0. 6% versus -1975. 8% for SVREW. At the gross margin level — before operating expenses — LFMD leads at 79. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ATRC: 95.

3% to $51. 33.

In this comparison, LFMD (1.

4% yield) pays a dividend. SVREW, GKOS, ATRC, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Glaukos Corporation (GKOS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

16), +454. 5% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GKOS: +454. 5%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SVREW (Technology) and GKOS (Healthcare) and ATRC (Healthcare) and LFMD (Healthcare) and NVCR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SVREW is a small-cap quality compounder stock; GKOS is a small-cap high-growth stock; ATRC is a small-cap quality compounder stock; LFMD is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. LFMD pays a dividend while SVREW, GKOS, ATRC, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.